NEW ADVANCES IN LIQUID BIOPSY TO INCREASE BIOMARK’S ASSAY PERFORMANCE
Vancouver, British Columbia – (August 13th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” has been published in the peer-reviewed journal Cancers. Rashid Ahmed, President and CEO, says, […]
The University of Maryland School of Medicine Enters Research Collaboration with BioMark Diagnostics
Vancouver, British Columbia – (June 26, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that BioMark and the University of Maryland School of Medicine (UMSOM) have entered into a collaboration related to the discovery and validation of biomarkers using a combinatorial technology approach. This collaboration follows several […]
BioMark Announces Debt Settlement
Vancouver, British Columbia – (June 18th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that it has arranged a voluntary debt to share settlement (the “Debt Settlement”) with certain directors and officers of the Company in connection with existing indebtedness related to services provided to the Company […]
BIOMARK ANNOUNCES NEW PATENT GRANTED IN UNITED STATES
Vancouver, British Columbia – (May 30th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX); (FSE: 20B); (OTCMKTS: BMKDF) is pleased to announce that its patent titled “DETECTION AND QUANTIFICATION OF ACETYLAMANTADINE IN URINE SAMPLES” has been recently granted in United States. Rashid Ahmed, President and CEO, says, “Granting of this patent expands and strengthens […]
REVISION ON TOTAL FUNDING SECURED BY BIOMARK AND ITS TEAM OF COLLABORATORS ON CHRP APPLICATION
Vancouver, British Columbia – (May 1st, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) would like to correct its news release dated on April 17th, 2019 announcing the approval of the application entitled “Development and clinical assessment of novel biomarker drugs targeting SSAT1 for detection and therapeutic monitoring of glioblastoma”, submitted […]
BIOMARK ANNOUNCES THE PRIVATE PLACEMENT
Vancouver, British Columbia – (April 9th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce a non-brokered Private Placement (the “Offering”). The Offering will be for up to 2,000,000 Units at a price of $0.10 to raise gross proceeds of up to $200,000. Each Unit is composed […]
BIOMARK CLOSES THE PRIVATE PLACEMENT OFFERING
April 16th, 2019 – Vancouver, British Columbia – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that further to its press release of April 9th, 2019, it has closed the non-brokered private placement for gross proceeds of $200,000.00 wherein BioMark issued 2,000,000 units at a price […]
BIOMARK AND ITS TEAM OF COLLABORATORS SECURE CHRP FUNDING
Vancouver, British Columbia – (April 17, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that its application entitled “Development and clinical assessment of novel biomarker drugs targeting SSAT1 for detection and therapeutic monitoring of glioblastoma”, submitted to the Collaborative Health Research Projects funding opportunity, has been approved. […]
BIOMARK’S ABSTRACT ACCEPTED FOR 2019 ASCO ONLINE PUBLICATION
Vancouver, British Columbia – (April 3, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the abstract submitted to the American Society of Clinical Oncology (ASCO) under Dr. Andrew Maksymiuk was accepted for online publication. The abstract was titled “Follow-up evaluation of outliers with elevated spermine-spermidine acetyltransferase-1 […]
BioMark Contributes Additional Scientific Publication
Vancouver, British Columbia – (March 14th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Use of amantadine as substrate for SSAT-1 activity as a reliable clinical diagnostic assay for breast and lung cancer” has been published in the peer-reviewed journal Future Science OA. […]
